title: Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
abstract: Colorectal cancer is the third most common form of malignancy, behind prostate and lung cancers. Despite recent advances in medicine, mortality from colorectal cancer remains high, highlighting the need for improved therapies. Numerous studies have demonstrated increased activation of EGFR and its family members (EGFRs), IGF-1R as well as c-Src in colorectal cancer. The current study was undertaken to examine the effectiveness of combination therapy of dasatinib (BMS-354825; Bristol-Myers Squibb), a highly specific inhibitor of Src family kinases (SFK) and a nontoxic dietary agent; curcumin (diferuloylmethane), in colorectal cancer in in vitro and in vivo experimental models. For the latter, we utilized C57BL/6 APC(Min+/-) mice. Initial in vitro studies revealed synergistic interactions between the two agents. Additionally, we have observed that combination treatment causes a much greater inhibition of the following metastatic processes than either agent alone: (i) colony formation, (ii) invasion through extracellular matrix and (iii) tubule formation by endothelial cells. Dasatinib affects the cell adhesion phenotype of colon cancer HCT-116 cells whereas the combination therapy enhances this effect to a greater extent. Preclinical investigation revealed that the combination therapy to be highly effective causing an over 95% regression of intestinal adenomas in Apc(Min+/-) mice, which could be attributed to decreased proliferation and increased apoptosis. In conclusion, our data suggest that combination treatment of dasatinib and curcumin could be a potential therapeutic strategy for colorectal cancer.
authors.affiliation: Veterans Affairs Medical Center, Detroit, MI 48201, USA.
authors.forename: Jyoti
authors.initials: J
authors.lastname: Nautiyal
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Banerjee
authors.forename: Shailender S
authors.initials: SS
authors.lastname: Kanwar
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Yu
authors.forename: Bhaumik B
authors.initials: BB
authors.lastname: Patel
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
authors.forename: Adhip P N
authors.initials: AP
authors.lastname: Majumdar
mesh_terms: D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D025601:Adenomatous Polyposis Coli Protein / Q000502:physiology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D000081247:CSK Tyrosine-Protein Kinase; D002448:Cell Adhesion; D002465:Cell Movement; D049109:Cell Proliferation / Q000187:drug effects*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D003474:Curcumin / Q000494:pharmacology*; D000069439:Dasatinib; D004357:Drug Synergism; D024202:Electrophoretic Mobility Shift Assay; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013844:Thiazoles / Q000494:pharmacology*; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D019061:src-Family Kinases
chemical_list: D025601:Adenomatous Polyposis Coli Protein; D000970:Antineoplastic Agents; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D012333:RNA, Messenger; D013844:Thiazoles; C541485:EGFR protein, mouse; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D017526:Receptor, IGF Type 1; D000081247:CSK Tyrosine-Protein Kinase; D019061:src-Family Kinases; C000631346:CSK protein, human; D003474:Curcumin; D000069439:Dasatinib
references.citation: Hum Pathol. 1999 Oct;30(10):1128-33
references.pmid: 10534157
references.citation: Ned Tijdschr Geneeskd. 2008 Apr 19;152(16):928-32
references.pmid: 18561788
references.citation: Am J Pathol. 2006 Mar;168(3):962-72
references.pmid: 16507911
references.citation: Cancer. 2005 Aug 15;104(4):879-90
references.pmid: 16007726
references.citation: Cancer Res. 2007 Jun 1;67(11):5389-96
references.pmid: 17545620
references.citation: Biochim Biophys Acta. 1995 Jun 9;1244(2-3):368-76
references.pmid: 7541245
references.citation: Gastroenterology. 1995 Feb;108(2):564-80
references.pmid: 7835600
references.citation: Clin Cancer Res. 2000 Feb;6(2):323-5
references.pmid: 10690506
references.citation: Cancer Res. 2008 May 1;68(9):3323-33
references.pmid: 18451159
references.citation: Int J Cancer. 2007 Jul 1;121(1):175-83
references.pmid: 17330230
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40
references.pmid: 12050094
references.citation: Science. 2004 Jul 16;305(5682):399-401
references.pmid: 15256671
references.citation: Gastroenterology. 1998 May;114(5):873-7
references.pmid: 9558273
references.citation: Cancer Res. 2005 Oct 15;65(20):9185-9
references.pmid: 16230377
references.citation: Pharm Res. 2009 Nov;26(11):2438-45
references.pmid: 19714451
references.citation: Mol Cell Biol. 1999 Sep;19(9):5923-9
references.pmid: 10454539
references.citation: Curr Opin Cell Biol. 1999 Apr;11(2):190-6
references.pmid: 10209155
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
references.pmid: 16203784
references.citation: Anticancer Res. 2006 Mar-Apr;26(2A):1029-37
references.pmid: 16619503
references.citation: Br J Cancer. 2001 Jul 20;85(2):303-11
references.pmid: 11461094
references.citation: Cancer Res. 2007 Apr 15;67(8):3818-26
references.pmid: 17440096
references.citation: Life Sci. 2006 Mar 27;78(18):2081-7
references.pmid: 16413584
references.citation: Cancer Lett. 2008 Oct 8;269(2):199-225
references.pmid: 18479807
references.citation: Cancer Res. 2007 Mar 15;67(6):2800-8
references.pmid: 17363602
references.citation: Ann Oncol. 2001 Jan;12(1):13-22
references.pmid: 11249040
references.citation: Gastroenterology. 2002 Oct;123(4):1191-204
references.pmid: 12360481
references.citation: Cancer Res. 2006 Jun 1;66(11):5542-8
references.pmid: 16740687
references.citation: Biochem Biophys Res Commun. 2000 Nov 2;277(3):757-63
references.pmid: 11062025
references.citation: Expert Opin Ther Targets. 2006 Feb;10(1):87-118
references.pmid: 16441231
references.citation: Mol Cancer Ther. 2007 Jul;6(7):1962-72
references.pmid: 17620427
references.citation: Mol Cancer Ther. 2005 Mar;4(3):435-42
references.pmid: 15767552
references.citation: Integr Cancer Ther. 2004 Dec;3(4):349-80
references.pmid: 15523106
references.citation: Nutr Cancer. 2006;55(2):185-94
references.pmid: 17044774
references.citation: Mol Cancer Ther. 2006 Dec;5(12):3014-22
references.pmid: 17148760
references.citation: Int J Cancer. 2008 Jan 15;122(2):267-73
references.pmid: 17918158
references.citation: Science. 1990 Jan 19;247(4940):322-4
references.pmid: 2296722
references.citation: Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
references.pmid: 7612182
references.citation: Anticancer Res. 2004 Sep-Oct;24(5A):2885-91
references.pmid: 15517892
references.citation: Carcinogenesis. 1993 Nov;14(11):2219-25
references.pmid: 8242846
references.citation: Gastroenterology. 2003 May;124(5):1337-47
references.pmid: 12730874
references.citation: Carcinogenesis. 1999 Mar;20(3):445-51
references.pmid: 10190560
references.citation: Carcinogenesis. 1992 Nov;13(11):2183-6
references.pmid: 1423891
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4233-44
references.pmid: 17634553
references.citation: Cancer Lett. 2001 Oct 30;172(2):111-8
references.pmid: 11566484
references.citation: Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30
references.pmid: 12020799
references.citation: Cancer Metastasis Rev. 2003 Dec;22(4):337-58
references.pmid: 12884910
references.citation: Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1725-8
references.pmid: 4042250
references.citation: Cancer Res. 1995 Jan 15;55(2):259-66
references.pmid: 7812955
references.citation: Acta Oncol. 1998;37(3):285-9
references.pmid: 9677101
references.citation: N Engl J Med. 2006 Jun 15;354(24):2531-41
references.pmid: 16775234
references.citation: Hepatogastroenterology. 1997 Mar-Apr;44(14):435-40
references.pmid: 9164515
references.citation: J Med Chem. 2004 Dec 30;47(27):6658-61
references.pmid: 15615512
references.citation: Cancer Lett. 2009 Oct 8;283(2):143-51
references.pmid: 19398150
references.citation: Genes Dev. 1999 Nov 15;13(22):2905-27
references.pmid: 10579998
references.citation: Clin Cancer Res. 2004 Oct 15;10(20):6847-54
references.pmid: 15501961